Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase
- PMID: 20304099
- DOI: 10.1016/j.cgh.2010.03.006
Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase
Abstract
Background & aims: Little is known about the level of hepatitis B virus (HBV) DNA in individuals with chronic, inactive HBV infections. Patients who test positive for the antibody to hepatitis B e antigen (anti-HBe) and have normal levels of alanine aminotransferase for more than 10 years have a low risk of HBV reactivation and are considered to be inactive carriers. We investigated HBV DNA levels in inactive carriers and identified factors that correlated with this state among anti-HBe-positive carriers with HBV DNA levels of 10(4) copies/mL or greater (5.26 copies/mL = 1 IU/mL).
Methods: HBV DNA levels were assayed in 250 inactive carriers with persistently normal alanine aminotransferase levels for more than 10 years. Clinical and virologic features were compared between inactive carriers (with HBV DNA levels > or =10(4) copies/mL) and age-matched patients with HBe antigen-negative chronic hepatitis (controls, n = 90).
Results: The median level of HBV DNA among inactive carriers was 3.70 log(10) copies/mL (range, undetectable to 5.98 log(10) copies/mL). Ninety (36%) had levels of 10(4) copies/mL or greater. Compared with control patients, significant differences of inactive carriers included sex (more female patients), lower HBV DNA levels, and lower prevalence of genotype C virus and the basal core promoter mutation T1762/A1764. The prevalence of the precore mutation A1896 was similar between groups. Multiple logistic regression analyses identified male sex, HBV DNA levels greater than 10(5) copies/mL, and the basal core promoter mutation as independent factors that correlated with active disease.
Conclusions: Nearly 40% of inactive carriers had HBV DNA levels of 10(4) copies/mL or greater. Female sex, HBV DNA levels of 10(4) to 10(5) copies/mL, and wild-type basal core promoter correlated with inactive carrier state.
Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
[Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].Mikrobiyol Bul. 2007 Jan;41(1):87-93. Mikrobiyol Bul. 2007. PMID: 17427556 Turkish.
-
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.Am J Gastroenterol. 2003 Oct;98(10):2261-7. doi: 10.1111/j.1572-0241.2003.07715.x. Am J Gastroenterol. 2003. PMID: 14572577
-
Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study.Liver Int. 2007 Aug;27(6):806-15. doi: 10.1111/j.1478-3231.2007.01505.x. Liver Int. 2007. PMID: 17617124
-
Occult hepatitis B virus infection.Transfus Clin Biol. 2004 Feb;11(1):18-25. doi: 10.1016/j.tracli.2003.11.007. Transfus Clin Biol. 2004. PMID: 14980545 Review.
-
The prognosis and management of inactive HBV carriers.Liver Int. 2016 Jan;36 Suppl 1:100-4. doi: 10.1111/liv.13006. Liver Int. 2016. PMID: 26725905 Review.
Cited by
-
Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection.Br J Cancer. 2012 Dec 4;107(12):2010-5. doi: 10.1038/bjc.2012.474. Epub 2012 Oct 18. Br J Cancer. 2012. PMID: 23079574 Free PMC article.
-
Gamma-glutamyl Transpeptidase to Platelet Ratio Predicts Liver Injury in Hepatitis B e Antigen-negative Chronic Hepatitis B Patients With Normal Alanine Aminotransferase.J Clin Transl Hepatol. 2022 Apr 28;10(2):247-253. doi: 10.14218/JCTH.2021.00151. Epub 2021 Jul 14. J Clin Transl Hepatol. 2022. PMID: 35528978 Free PMC article.
-
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.Hepatol Int. 2012 Jun;6(3):531-61. doi: 10.1007/s12072-012-9365-4. Epub 2012 May 17. Hepatol Int. 2012. PMID: 26201469
-
Nature of Host Immunity during Hepatitis B Virus Infection and designing Immune Therapy.Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):42-46. doi: 10.5005/jp-journals-10018-1256. Epub 2018 May 1. Euroasian J Hepatogastroenterol. 2018. PMID: 29963460 Free PMC article. Review.
-
Immune therapy for hepatitis B.Ann Transl Med. 2016 Sep;4(18):335. doi: 10.21037/atm.2016.08.48. Ann Transl Med. 2016. PMID: 27761439 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources